Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm

References

• Abd El-Aziz TM, Stockand JD. 2020. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) – an update on the status. Infect Genet Evol. 83:104327.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, et al. 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. Subbarao K, editor. MBio. 9(2):18.
   Web of Science ®Google Scholar
• Amirian ES, Levy JK. 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 9:100128.
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 300(5626):1763–1767.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, et al. 2016. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infect Dis. 22(9):1554–1561.
   PubMed Web of Science ®Google Scholar
• Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (Favipiravir) induces lethal mutagenesis in influenza a H1N1 Viruses in vitro. J Virol. 87(7):3741–3751.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. 2020. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. DOI:10.1056/NEJMoa2007764.
   Web of Science ®Google Scholar
• Broekhuysen J, Stockis A, Lins RL, Graeve JD, Rossignol JF. 2000. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther. 38(8):387–394.
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178:104787
   PubMed Web of Science ®Google Scholar
• Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. 2007. Disappearance of antibodies to SARS-associated Coronavirus after recovery. N Engl J Med. 357(11):1162–1163.
   PubMed Web of Science ®Google Scholar
• Cavanagh D. 2005. Coronaviruses in poultry and other birds. Avian Pathol. 34(6):439–448.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, Yuen K-Y. 2020. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 9(1):221–236.
   PubMed Web of Science ®Google Scholar
• Chauhan A, Tikoo A. 2015. The enigma of the clandestine association between chloroquine and HIV-1 infection. HIV Med. 16(10):585–590.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Hulot J-S, Amoura Z, Leroux G, Lechat P, Funck-Brentano C, Piette J-C. 2007. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology. 46(5):808–810.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. 2020. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. DOI:10.1101/2020.03.16.20036145.
   Google Scholar
• Dubreuil L, Houcke I, Mouton Y, Rossignol JF. 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother. 40(10):2266–2270.
   PubMed Web of Science ®Google Scholar
• Eickmann M, Gravemann U, Handke W, Tolksdorf F, Reichenberg S, Müller TH, Seltsam A. 2018. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion. 58(9):2202–2207.
   PubMed Web of Science ®Google Scholar
• Gratton R, Tricarico PM, Guimaraes RL, Celsi F, Crovella S. 2018. Lopinavir/ritonavir treatment induces oxidative stress and caspaseindependent apoptosis in human glioblastoma U-87 MG cell line. Curr Hiv Res. 16(2):106–112.
   PubMed Web of Science ®Google Scholar
• Hilgenfeld R. 2014. From SARS to MERS: crystallographic studies on Coronaviral proteases enable antiviral drug design. Febs J. 281(18):4085–4096.
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, et al. 2020. First case of 2019 Novel Coronavirus in the United States. N Engl J Med. 382(10):929–936.
   PubMed Web of Science ®Google Scholar
• Japanese flu drug ‘clearly effective’ in treating coronavirus, says China. 2020 [accessed 2020 Mar 25]. https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says.
   Google Scholar
• Kin N, Miszczak F, Diancourt L, Caro V, Moutou F, Vabret A, Ar Gouilh M. 2016. Comparative molecular epidemiology of two closely related coronaviruses, bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43), reveals a different evolutionary pattern. Infect Genet Evol. 40:186–191.
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA. 107(2):882–887.
   PubMed Web of Science ®Google Scholar
• Lee S. 2015. Costly lessons from the 2015 middle east respiratory syndrome Coronavirus outbreak in Korea. J Prev Med Public Health. 48(6):274–276.
   PubMedGoogle Scholar
• Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. 2020. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-infected pneumonia. N Engl J Med. 382(13):1199–1207.
   PubMed Web of Science ®Google Scholar
• Lippi G, Plebani M. 2020. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 58(7):1063–1069.
   Google Scholar
• Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, et al. 2017. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 7(1):43395
   PubMed Web of Science ®Google Scholar
• Lu S, Wang Y, Chen Y, Wu B, Qin K, Zhao J, Lou Y, Tan W. 2017. Discovery of a novel canine respiratory coronavirus support genetic recombination among betacoronavirus1. Virus Res. 237:7–13.
   PubMed Web of Science ®Google Scholar
• Lv C, Liu W, Wang B, Dang R, Qiu L, Ren J, Yan C, Yang Z, Wang X. 2018. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res. 159:55–62.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang Y, Liang X, Lou F, Oglesbee M, Krakowka S, Li J. 2015. Origin, evolution, and virulence of porcine deltacoronaviruses in the United States. Parker J, Griffin DE, editors. MBio. 6(2):e00064-15.
   Web of Science ®Google Scholar
• Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, Coppes RP, Engedal N, Mari M, Reggiori F, et al. 2018. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 14(8):1435–1455.
   PubMed Web of Science ®Google Scholar
• Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, Sánchez-Seco P, Lago M, Figueira JC, Fernández-Puntero B, Viejo A, et al. 2015. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med. 3(7):554–562.
   PubMed Web of Science ®Google Scholar
• Morse JS, Lalonde T, Xu S, Liu WR. 2020. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 21(5):730–738.
   PubMed Web of Science ®Google Scholar
• Rismanbaf A, Zarei S. 2020. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad ic Emerg Med. 8(1):17.
   PubMed Web of Science ®Google Scholar
• Rossignol J-F. 2014. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 110:94–103.
   PubMed Web of Science ®Google Scholar
• Rossignol J-F. 2016. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 9(3):227–230.
   PubMed Web of Science ®Google Scholar
• Sahraei Z, Shabani M, Shokouhi S, Saffaei A. 2020. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 55(4):105945.
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. 2003. Cauda R. effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 3(11):722–727.
   PubMed Web of Science ®Google Scholar
• Shakya A, Bhat HR, Ghosh SK. 2018. Update on Nitazoxanide: a multifunctional chemotherapeutic agent. Curr Drug Discov Technol. 15(3):201–213.
   PubMedGoogle Scholar
• Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, et al. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al. 2020. Treatment of 5 critically Ill patients with COVID-19 with Convalescent Plasma. JAMA. 323(16):1582.
   PubMed Web of Science ®Google Scholar
• Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S. 2013. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radic Biol Med. 65:778–788.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2020. Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. [accessed 2020 May 12]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-againstuse-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or.
   Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2:69.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, et al. 2013. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 501(7468):551–555.
   PubMed Web of Science ®Google Scholar
• Weiss SR, Navas-Martin S. 2005. Coronavirus Pathogenesis and the emerging pathogen severe acute respiratory syndrome Coronavirus. Microbiol Mol Biol Rev. 69(4):635–664.
   PubMed Web of Science ®Google Scholar
• Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, et al. 2016. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res. 126:62–68.
   PubMed Web of Science ®Google Scholar
• White AC. Jr 2004. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev anti Infect Ther. 2(1):43–49.
   PubMedGoogle Scholar
• Yazdany J, Kim AHJ. 2020. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 172(11):754–755.
   PubMed Web of Science ®Google Scholar